Frequency categories are defined according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Blood and lymphatic system disorders
Uncommon:
Bleeding tendencies due to hypoprothrombinaemia (Vitamin K deficiency) as well as Vitamin A (night blindness has been reported rarely) and D deficiencies.
Metabolism and nutrition disorders
Uncommon:
Anorexia, hyperchloremic acidosis in children
Gastrointestinal disorders
Vey common:
Constipation. Predisposing factors for most of these complaints when Questran is used as a cholesterol lowering agent are: high dose and increased age (more than 60 years old). Most instances of constipation are mild, transient and controlled with conventional therapy.
Some patients require a temporary decrease in dosage or discontinuation of therapy.
Uncommon:
Abdominal discomfort, flatulence, nausea, vomiting, diarrhoea, heartburn, dyspepsia and steatorrhea,
Rare:
Reports of intestinal obstruction have been received post marketing, including deaths in paediatric patients.
Skin and subcutaneous tissue disorders
Uncommon:
Rash and irritation of skin, tongue and perianal area.
Musculoskeletal and connective tissue disorders
Uncommon:
Osteoporosis.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.